Showing results (171-180 of 185) with videos related to

Sort By:
Pageof 19
European Urology|July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaJens Bedke, Brian I Rini, Elizabeth R Plimack, et al.
Scientific Reports|February 27, 2026
Development and characterization of an inducible Tensin1 deficient transgenic murine modelKsenija Bernau, Kelsey Holbert, Ivy S McDermott, et al.
CNS Drug Reviews|June 5, 2004
ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disordersLynne E Rueter, David J Anderson, Clark A Briggs, et al.
Pain|February 20, 2010
Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent painBaoXi Gao, Markus Hierl, Kristie Clarkin, et al.
Nature Medicine|August 1, 2025
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trialBrian I Rini, Elizabeth R Plimack, Viktor Stus, et al.
Neuropharmacology|May 21, 2018
Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors: Improved bioavailability enhances anticonvulsant efficacyJ M Witkin, J L Smith, X Ping, et al.
The New England Journal of Medicine|February 20, 2019
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaBrian I Rini, Elizabeth R Plimack, Viktor Stus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 22, 2025
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)H-M Lin, T Scheinberg, N Portman, et al.
Prostate Cancer and Prostatic Diseases|August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 studyJulie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
The Lancet. Gastroenterology & Hepatology|September 21, 2023
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trialJohn V Reynolds, Shaun R Preston, Brian O'Neill, et al.
Pageof 19